

# Sarah Schott

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3216022/publications.pdf>

Version: 2024-02-01

121  
papers

3,642  
citations

156536

32  
h-index

169272

56  
g-index

137  
all docs

137  
docs citations

137  
times ranked

7300  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer. <i>Breast Care</i> , 2022, 17, 199-207.	0.8	12
2	Total circulating microRNA level as an independent prognostic marker for risk stratification in breast cancer. <i>British Journal of Cancer</i> , 2022, 127, 156-162.	2.9	8
3	Assessing the influence of the menstrual cycle on APT CEST-MRI in the human breast. <i>Magnetic Resonance Imaging</i> , 2022, 91, 24-31.	1.0	2
4	Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany: A retrospective cohort study. <i>Cancer Medicine</i> , 2021, 10, 7747-7758.	1.3	7
5	Breast cancer risk in <i>BRCA1/2</i> mutation carriers and noncarriers under prospective intensified surveillance. <i>International Journal of Cancer</i> , 2020, 146, 999-1009.	2.3	32
6	A novel normalization for amide proton transfer CEST MRI to correct for fat signal-induced artifacts: application to human breast cancer imaging. <i>Magnetic Resonance in Medicine</i> , 2020, 83, 920-934.	1.9	26
7	Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 425-433.	1.1	16
8	The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. <i>Nature Communications</i> , 2020, 11, 4740.	5.8	78
9	The work and training situation for young physicians undergoing specialty training in gynecology and obstetrics in Germany: an assessment of the status quo. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 635-647.	0.8	9
10	Relaxation-compensated CEST (chemical exchange saturation transfer) imaging in breast cancer diagnostics at 7T. <i>European Journal of Radiology</i> , 2020, 129, 109068.	1.2	22
11	Cancer surveillance and distress among adult pathogenic <i>TP53</i> germline variant carriers in Germany: A multicenter feasibility and acceptance survey. <i>Cancer</i> , 2020, 126, 4032-4041.	2.0	20
12	Emergency consultations in obstetrics: identification of decisive, contributing and associated factors. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 821-828.	0.8	1
13	Evaluation of Storage Tubes for Combined Analysis of Circulating Nucleic Acids in Liquid Biopsies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 704.	1.8	44
14	A plasma metabolite panel as biomarkers for early primary breast cancer detection. <i>International Journal of Cancer</i> , 2019, 144, 2833-2842.	2.3	50
15	Adherence to gynecological screening impacted by experienced orthodontic treatment in childhood. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 167-171.	0.8	2
16	The impact of a cervical dysplasia diagnosis on individual cancer prevention habits over time: a bicentric case-control study. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 847-855.	0.8	3
17	Women's Attitudes Toward Self-Monitoring of Their Pregnancy Using Noninvasive Electronic Devices: Cross-Sectional Multicenter Study. <i>JMIR MHealth and UHealth</i> , 2019, 7, e11458.	1.8	19
18	Abstract A114: Omental fat in ovarian cancer induces metabolic and immune alterations. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	Abstract A086: Omental fat in ovarian cancer induces lymphangiogenesis. , 2019, , .		0
20	Abstract A069: NIM15 blockade â€“ A new stroma-targeting approach for the treatment of epithelial ovarian cancer. , 2019, , .		0
21	Abstract 571: The shared mutation and neoantigen landscape of MMR-deficient colorectal cancers suggests immunoeediting during tumor evolution. , 2019, , .		0
22	Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 69-82.	1.1	50
23	A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow. <i>Cancer Research</i> , 2018, 78, 129-142.	0.4	32
24	Implementation of a novel efficacy score to compare sealing and cutting devices in a porcine model. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 1002-1011.	1.3	6
25	Oncotype DXÂ® in breast cancer patients: clinical experience, outcome and follow-upâ€”a caseâ€”control study. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 443-447.	0.8	8
26	Acceptance of a new non-invasive fetal monitoring system and attitude for telemedicine approaches in obstetrics: a caseâ€”control study. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 1085-1093.	0.8	11
27	Identifying and predicting distinct distress trajectories following a breast cancer diagnosis - from treatment into early survival. <i>Journal of Psychosomatic Research</i> , 2018, 115, 6-13.	1.2	25
28	Impact of a cervical dysplasia and its treatment on quality of life and sexual function. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 737-745.	0.8	9
29	Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals. <i>International Journal of Molecular Sciences</i> , 2018, 19, 900.	1.8	18
30	Evaluation of the methodological quality of articles on autologous breast reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2018, 71, 1286-1294.	0.5	1
31	A Web-Based Survey Assessing the Attitudes of Health Care Professionals in Germany Toward the Use of Telemedicine in Pregnancy Monitoring: Cross-Sectional Study. <i>JMIR MHealth and UHealth</i> , 2018, 6, e10063.	1.8	24
32	Hematological Malignancies in Adults With a Family Predisposition. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2018, 115, 848-854.	0.6	9
33	Topography of cancer-associated immune cells in human solid tumors. <i>ELife</i> , 2018, 7, .	2.8	206
34	Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer. <i>Oncolmmunology</i> , 2017, 6, e1274477.	2.1	30
35	Women at familial risk of breast cancer electing for prophylactic mastectomy: frequencies, procedures, and decision-making characteristics. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1451-1458.	0.8	9
36	Epigenetic regulation of indoleamine-2,3-dioxygenase 1 expression in human breast cancer. <i>Breast</i> , 2017, 32, S31-S32.	0.9	0

#	ARTICLE	IF	CITATIONS
37	European Network of Trainees in Obstetrics and Gynaecology: experiences from the 2016 exchange programme in Turin, Italy. Archives of Gynecology and Obstetrics, 2017, 295, 265-267.	0.8	1
38	The association between breast cancer and S100P methylation in peripheral blood by multicenter caseâ€“control studies. Carcinogenesis, 2017, 38, 312-320.	1.3	41
39	Inter-rater reliability and double reading analysis of an automated three-dimensional breast ultrasound system: comparison of two independent examiners. Archives of Gynecology and Obstetrics, 2017, 296, 571-582.	0.8	9
40	Part-time employment of gynecologists and obstetricians: a sub-group analysis of a Germany-wide survey of residents. Archives of Gynecology and Obstetrics, 2017, 295, 133-140.	0.8	9
41	Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases. Journal of Bone and Mineral Research, 2017, 32, 536-548.	3.1	9
42	Duty Rosters and Workloads of Obstetricians in Germany: Results of a Germany-wide Survey. Geburtshilfe Und Frauenheilkunde, 2017, 77, 894-903.	0.8	7
43	Investigation of Global Methylation in Peripheral Blood from Breast Cancer Patients. Journal of Molecular Biomarkers & Diagnosis, 2017, 01, .	0.4	0
44	Familial breast cancer: Genetic counseling over time, including patients' expectations and initiators considering the Angelina Jolie effect. PLoS ONE, 2017, 12, e0177893.	1.1	14
45	Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence. Oncotarget, 2017, 8, 54537-54547.	0.8	34
46	<i>HYAL2</i> methylation in peripheral blood as a potential marker for the detection of pancreatic cancer: a case control study. Oncotarget, 2017, 8, 67614-67625.	0.8	10
47	The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro. Oncotarget, 2017, 8, 76935-76948.	0.8	5
48	The activity of the conjugated antimetabolite 5-FdU-ECyd against platinum-resistant ovarian cancer.. Journal of Clinical Oncology, 2017, 35, e17077-e17077.	0.8	0
49	DNA methylation array analysis identifies breast cancer associated <i>RPTOR</i> , <i>MGRN1</i> and <i>RAPSN</i> hypomethylation in peripheral blood DNA. Oncotarget, 2016, 7, 64191-64202.	0.8	33
50	Detection of Human Papillomavirus Infection in Patients with Vaginal Intraepithelial Neoplasia. PLoS ONE, 2016, 11, e0167386.	1.1	53
51	Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer. International Journal of Cancer, 2016, 138, 2499-2509.	2.3	31
52	Does knowledge of fetal outcome influence the interpretation of intrapartum cardiotocography and subsequent clinical management? A multicentre European study. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 2208-2217.	1.1	23
53	Prevalence of <i>BRCA1/2</i> germline mutations in 21â€“401 families with breast and ovarian cancer. Journal of Medical Genetics, 2016, 53, 465-471.	1.5	179
54	Senology in Gynaecology Specialist Training: a Baseline Survey from 2014. Geburtshilfe Und Frauenheilkunde, 2016, 76, 564-569.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 289-299.	1.1	23
56	Plasma S100P level as a novel prognostic marker of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 329-338.	1.1	18
57	Expectations for Endoscopic Training During Gynaecological Specialty Training – Results of a Germany-wide Survey. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 1330-1338.	0.8	4
58	Long-term experiences with genetic consultation in people with hereditary breast and ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1011-1018.	0.8	10
59	Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. <i>Carcinogenesis</i> , 2016, 37, 461-470.	1.3	122
60	Change of Patient-Reported Aesthetic Outcome Over Time and Identification of Factors Characterizing Poor Aesthetic Outcome After Breast-Conserving Therapy: Long-Term Results of a Prospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 1744-1751.	0.7	33
61	European trainee exchange: experiences due the ENTOG exchange programme 2015 in Utrecht, the Netherlands. <i>Archives of Gynecology and Obstetrics</i> , 2016, 293, 235-237.	0.8	0
62	Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment. <i>Annals of Surgical Oncology</i> , 2016, 23, 757-766.	0.7	15
63	Abstract A102: The fat in ovarian cancer: Immune-dependent tumor-promoting effects. <i>Cancer Immunology Research</i> , 2016, 4, A102-A102.	1.6	2
64	Abstract B054: Evaluation of NY-BR-1 as a suitable antigen for CAR based immunotherapy. , 2016, , .		0
65	In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis. <i>Investigational New Drugs</i> , 2015, 33, 816-826.	1.2	10
66	Evaluation of an automated breast 3D-ultrasound system by comparing it with hand-held ultrasound (HHUS) and mammography. <i>Archives of Gynecology and Obstetrics</i> , 2015, 291, 889-895.	0.8	41
67	Long-term objective esthetic outcome after breast-conserving therapy. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 345-351.	1.1	46
68	Becoming a resident in Germany: an experience-based practical guideline. <i>Archives of Gynecology and Obstetrics</i> , 2015, 291, 457-460.	0.8	2
69	<sc>DNA</sc> methylation array analyses identified breast cancer-associated <sc><i>HYAL2</i></sc> methylation in peripheral blood. <i>International Journal of Cancer</i> , 2015, 136, 1845-1855.	2.3	53
70	Abstract P6-17-02: Inhibition of osteolytic tumor growth by 5-FdU-alendronate, a bisphosphonate conjugate that maintains bone formation: Implications for treatment of osteolytic bone lesions. , 2015, , .		0
71	Evaluation of Virtual Touch Tissue Imaging Quantification, a New Shear Wave Velocity Imaging Method, for Breast Lesion Assessment by Ultrasound. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	77
72	Psychosomatic Primary Care in Gynecology – Assessment and Acceptance by Residents for Obstetrics and Gynecology in Germany. <i>Geburtshilfe Und Frauenheilkunde</i> , 2014, 74, 569-573.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Presence of relaxin <sup>2</sup> , oxytocin and their receptors in uterosacral ligaments of premenopausal patients with and without pelvic organ prolapse. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2014, 93, 991-996.	1.3	5
74	Four-country meeting on residency in France, Germany, The Netherlands and UK: 4 countries, 4 ways. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 833-837.	0.8	3
75	Quality of life and anxiety of patients affected by the PIP/Rofil Medical breast implant recall: results from a prospective monocentre cohort study. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 957-962.	0.8	0
76	Recall management of patients with Rofil Medical breast implants. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2014, 67, 939-945.	0.5	3
77	Four countries, four ways of discussing low-risk pregnancy and normal delivery: in France, Germany, The Netherlands, and the United Kingdom. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 451-456.	0.8	6
78	Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 1079-1085.	0.8	2
79	Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 163-174.	1.1	142
80	Induction of apoptosis in cervical cancer cells by the duplex drug 5-FdU <sup>2</sup> ECyd, coupling 2 <sup>2</sup> -deoxy-5-fluorouridine and 3 <sup>2</sup> -C-ethinylcytidine. <i>Gynecologic Oncology</i> , 2014, 135, 342-348.	0.6	6
81	Comparison of molecular abnormalities in vulvar and vaginal melanomas. <i>Modern Pathology</i> , 2014, 27, 1386-1393.	2.9	70
82	Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. <i>BMC Cancer</i> , 2014, 14, 512.	1.1	65
83	Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 451-460.	1.1	8
84	Predictors of early poor aesthetic outcome after breast-conserving surgery in patients with breast cancer: Initial results of a prospective cohort study at a single institution. <i>Journal of Surgical Oncology</i> , 2014, 110, 801-806.	0.8	34
85	Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1053-1060.	2.0	42
86	Normal breast tissue stiffness measured by a new ultrasound technique: Virtual touch tissue imaging quantification (VTIQ). <i>European Journal of Radiology</i> , 2013, 82, e676-e679.	1.2	61
87	Effect of duplex drugs linking 2 <sup>2</sup> -deoxy-5-fluorouridine (5-FdU) with 3 <sup>2</sup> -C-ethinylcytidine (ECyd) on hepatoblastoma cell lines. <i>Pediatric Surgery International</i> , 2013, 29, 121-127.	0.6	8
88	The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 503-510.	1.1	118
89	Circulating Fibronectin Controls Tumor Growth. <i>Neoplasia</i> , 2013, 15, 925-IN24.	2.3	55
90	Circulating microRNAs in plasma as early detection markers for breast cancer. <i>International Journal of Cancer</i> , 2013, 132, 1602-1612.	2.3	227

#	ARTICLE	IF	CITATIONS
91	Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility. <i>Geburtshilfe Und Frauenheilkunde</i> , 2013, 73, 932-940.	0.8	55
92	Plasma MicroRNA Panel for Minimally Invasive Detection of Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e76729.	1.1	112
93	19p13.1 Is a Triple-Negative-Specific Breast Cancer Susceptibility Locus. <i>Cancer Research</i> , 2012, 72, 1795-1803.	0.4	100
94	Extent of Primary Breast Cancer Surgery: Standards and Individualized Concepts. <i>Breast Care</i> , 2012, 7, 364-369.	0.8	11
95	Expression of oxytocin and its receptor in healthy and varicose great saphenous veins. <i>Pathology</i> , 2012, 44, 670-673.	0.3	4
96	Laparoscopically Assisted Vaginal Hysterectomy in a Patient With Micro-Invasive Cervical Cancer After Two Liver Transplantations. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2012, 34, 363-366.	0.3	2
97	Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 5972-5982.	3.2	231
98	11q13 is a susceptibility locus for hormone receptor positive breast cancer. <i>Human Mutation</i> , 2012, 33, 1123-1132.	1.1	35
99	Cytotoxicity of new duplex drugs linking 3'-ethynylcytidine and 5'-fluoro-2'-deoxyuridine against human melanoma cells. <i>International Journal of Cancer</i> , 2012, 131, 2165-2174.	2.3	10
100	Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay. <i>Investigational New Drugs</i> , 2012, 30, 1750-1755.	1.2	5
101	Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 725-734.	1.1	1
102	Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 353-362.	2.0	196
103	A Novel Role for Relaxin-2 in the Pathogenesis of Primary Varicosis. <i>PLoS ONE</i> , 2012, 7, e39021.	1.1	8
104	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). <i>PLoS ONE</i> , 2012, 7, e42380.	1.1	51
105	Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1090-1090.	0.8	0
106	Change of aesthetic and functional outcome over time and their relationship to quality of life after breast conserving therapy. <i>European Journal of Surgical Oncology</i> , 2011, 37, 116-121.	0.5	45
107	Long-term remission of an advanced recurrent endometrial cancer in a heavily pretreated patient using a combined regimen with bevacizumab and metronomic cyclophosphamide. <i>Anti-Cancer Drugs</i> , 2011, 22, 822-824.	0.7	5
108	Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine. <i>Investigational New Drugs</i> , 2011, 29, 248-257.	1.2	12



#	ARTICLE	IF	CITATIONS
109	ATP chemosensitivity testing of new antitumor duplex drugs linking 3'-C-ethynylcytidine (ECyd) and 2-Å'-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof. <i>Investigational New Drugs</i> , 2011, 29, 506-513.	1.2	8
110	Cytostatic activity of the duplex drug linking 2-Å'-deoxy-5-fluorouridine (5Fdu) with 3-Å'-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines. <i>Investigational New Drugs</i> , 2011, 29, 1294-1302.	1.2	9
111	Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 549-554.	1.1	18
112	Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 401-411.	2.0	4
113	Therapeutic effects of metformin in breast cancer: involvement of the immune system?. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1221-1225.	2.0	17
114	Acceptance of oral chemotherapy in breast cancer patients - a survey study. <i>BMC Cancer</i> , 2011, 11, 129.	1.1	31
115	Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature. <i>Breast Care</i> , 2011, 6, 395-398.	0.8	1
116	Potency of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluoro-2'-deoxyuridine against human melanoma in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2011, 29, 8570-8570.	0.8	0
117	Breast Cancer and Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2010, 118, 673-677.	0.6	27
118	Cystic adenomatoid malformation of the lung causing hydrops fetalis: case report and review of the literature. <i>Archives of Gynecology and Obstetrics</i> , 2009, 280, 293-296.	0.8	24
119	Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 303-310.	1.4	5
120	Synthesis and in vitro activities of new anticancer duplex drugs linking 2-Å'-deoxy-5-fluorouridine (5-FdU) with 3-Å'-C-ethynylcytidine (ECyd) via a phosphodiester bonding. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6824-6831.	1.4	17
121	In Vivo and in Vitro Activity And Mechanism Of Action of the Multidrug Cytarabine-L-Glycerlyl-Fluorodeoxyuridine. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2007, 26, 1619-1624.	0.4	8